PearlMatrix™ Hits the OR: First U.S. Patient Post-FDA Approval

Subscribe today to listen to this content Get Access

The champagne corks are probably still rolling around at Cerapedics HQ. In June 2025, the company secured FDA premarket approval for its PearlMatrix™ P-15 Peptide Enhanced Bone Graft — and now they’ve marked another milestone: the first U.S. patient treated post-approval.

Approved for single-level transforaminal lumbar interbody fusion (TLIF) in adults with degenerative disc disease, PearlMatrix isn’t just another bone graft — Cerapedics says it’s the first and only bone growth accelerator proven to speed lumbar fusion, showing statistically superior fusion rates in single-level TLIF procedures.